Cyclophosphamide Treatment Options in Sacramento, CA (Updated 6/25)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377

Recruiting

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/05/2025

Locations: Sutter Auburn Faith Hospital, Auburn, California +32 locations

Sutter Auburn Faith Hospital, Auburn, California

AIS Cancer Center at San Joaquin Community Hospital, Bakersfield, California

Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California

Tower Cancer Research Foundation, Beverly Hills, California

City of Hope Comprehensive Cancer Center, Duarte, California

Palo Alto Medical Foundation-Fremont, Fremont, California

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

City of Hope at Irvine Lennar, Irvine, California

City of Hope Antelope Valley, Lancaster, California

Loma Linda University Medical Center, Loma Linda, California

City of Hope at Long Beach Elm, Long Beach, California

Cedars Sinai Medical Center, Los Angeles, California

Memorial Medical Center, Modesto, California

City of Hope Newport Beach, Newport Beach, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

Desert Regional Medical Center, Palm Springs, California

Palo Alto Medical Foundation Health Care, Palo Alto, California

Huntington Memorial Hospital, Pasadena, California

Sutter Roseville Medical Center, Roseville, California

Sutter Medical Center Sacramento, Sacramento, California

Zuckerberg San Francisco General Hospital, San Francisco, California

California Pacific Medical Center-Pacific Campus, San Francisco, California

Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California

Providence Medical Foundation - Santa Rosa, Santa Rosa, California

Sutter Pacific Medical Foundation, Santa Rosa, California

Providence Santa Rosa Memorial Hospital, Santa Rosa, California

City of Hope South Pasadena, South Pasadena, California

Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California

Cedars-Sinai Cancer - Tarzana, Tarzana, California

City of Hope South Bay, Torrance, California

Torrance Memorial Physician Network - Cancer Care, Torrance, California

City of Hope Upland, Upland, California

Sutter Solano Medical Center/Cancer Center, Vallejo, California

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma

Register for Updates

Learn More ›

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410

Recruiting

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi... Read More

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone. Read Less

Gender:

ALL

Ages:

Between 5 years and 60 years

Trial Updated:

06/05/2025

Locations: City of Hope Corona, Corona, California +33 locations

City of Hope Corona, Corona, California

Kaiser Permanente Downey Medical Center, Downey, California

City of Hope Comprehensive Cancer Center, Duarte, California

Kaiser Permanente Dublin, Dublin, California

Kaiser Permanente-Fremont, Fremont, California

Kaiser Permanente-Fresno, Fresno, California

City of Hope Seacliff, Huntington Beach, California

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

City of Hope at Irvine Lennar, Irvine, California

City of Hope Antelope Valley, Lancaster, California

Loma Linda University Medical Center, Loma Linda, California

Miller Children's and Women's Hospital Long Beach, Long Beach, California

City of Hope at Long Beach Elm, Long Beach, California

Children's Hospital Los Angeles, Los Angeles, California

Cedars Sinai Medical Center, Los Angeles, California

Kaiser Permanente-Modesto, Modesto, California

City of Hope Newport Beach, Newport Beach, California

Kaiser Permanente-Oakland, Oakland, California

Children's Hospital of Orange County, Orange, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

Kaiser Permanente Downtown Commons, Sacramento, California

Kaiser Permanente-South Sacramento, Sacramento, California

Rady Children's Hospital - San Diego, San Diego, California

Kaiser Permanente-San Francisco, San Francisco, California

Kaiser Permanente-Santa Teresa-San Jose, San Jose, California

Kaiser Permanente San Leandro, San Leandro, California

Kaiser San Rafael-Gallinas, San Rafael, California

Kaiser Permanente-Santa Rosa, Santa Rosa, California

City of Hope South Pasadena, South Pasadena, California

Kaiser Permanente-South San Francisco, South San Francisco, California

City of Hope South Bay, Torrance, California

City of Hope Upland, Upland, California

Kaiser Permanente-Vallejo, Vallejo, California

Kaiser Permanente-Walnut Creek, Walnut Creek, California

Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Register for Updates

Learn More ›

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

NCT04759586

Active Not Recruiting

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work... Read More

Gender:

ALL

Ages:

2 years and above

Trial Updated:

06/03/2025

Locations: UC Irvine Health Cancer Center-Newport, Costa Mesa, California +16 locations

Conditions: Primary Mediastinal Large B-Cell Lymphoma

Register for Updates

Learn More ›

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296

Recruiting

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab bi... Read More

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma. Read Less

Gender:

ALL

Ages:

30 years and below

Trial Updated:

05/29/2025

Locations: Kaiser Permanente Downey Medical Center, Downey, California +13 locations

Conditions: Neuroblastoma, Ganglioneuroblastoma, Nodular

Register for Updates

Learn More ›

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

NCT02981628

Recruiting

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.

Gender:

ALL

Ages:

Between 1 year and 21 years

Trial Updated:

05/22/2025

Locations: Kaiser Permanente Downey Medical Center, Downey, California +14 locations

Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma

Register for Updates

Learn More ›

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085

Recruiting

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin.... Read More

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy. Read Less

Gender:

ALL

Ages:

Between 1 year and 25 years

Trial Updated:

05/22/2025

Locations: Kaiser Permanente Downey Medical Center, Downey, California +18 locations

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia

Register for Updates

Learn More ›

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

NCT00006721

Active Not Recruiting

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy regimen is more effective in treating non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing 2 different monoclonal antibod... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/12/2025

Locations: Alta Bates Summit Comprehensive Cancer Center, Berkeley, California +8 locations

Conditions: Lymphoma

Register for Updates

Learn More ›

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865

Active Not Recruiting

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"), can also participate in this study. This study will be made up of Part 1A, Part 1B... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/12/2025

Locations: David Geffen School of Medicine at UCLA, Los Angeles, California +2 locations

Conditions: Diffuse Large B-cell Lymphoma (DLBCL)

Register for Updates

Learn More ›

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00972478

Active Not Recruiting

This phase I/II trial is studying the side effects and best dose of vorinostat when given together with rituximab and combination chemotherapy and to see how well it works in treating patients with newly diagnosed stage II, stage III, or stage IV diffuse large B-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Monoclonal antibodies, such as rituximab, can block cancer cell growth in diff... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/09/2025

Locations: Kaiser Permanente-Deer Valley Medical Center, Antioch, California +22 locations

Conditions: Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma

Register for Updates

Learn More ›

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

NCT02306161

Active Not Recruiting

This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Treatment with drugs that block the IGF-1R pathway, such as ganitumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor... Read More

Gender:

ALL

Ages:

50 years and below

Trial Updated:

05/08/2025

Locations: Kaiser Permanente Downey Medical Center, Downey, California +15 locations

Conditions: Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues

Register for Updates

Learn More ›

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02048813

Active Not Recruiting

This phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cel... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

05/08/2025

Locations: Kaiser Permanente-Anaheim, Anaheim, California +65 locations

Kaiser Permanente-Anaheim, Anaheim, California

Kaiser Permanente-Deer Valley Medical Center, Antioch, California

PCR Oncology, Arroyo Grande, California

Sutter Auburn Faith Hospital, Auburn, California

Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California

Kaiser Permanente-Baldwin Park, Baldwin Park, California

Kaiser Permanente-Bellflower, Bellflower, California

Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California

Mills-Peninsula Medical Center, Burlingame, California

Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California

Eden Hospital Medical Center, Castro Valley, California

Adventist Health Cancer Care Center Chico, Chico, California

John Muir Medical Center-Concord, Concord, California

Sutter Davis Hospital, Davis, California

Kaiser Permanente-Fontana, Fontana, California

Kaiser Permanente-Fremont, Fremont, California

Kaiser Permanente-Fresno, Fresno, California

Marin Cancer Care Inc, Greenbrae, California

Marin General Hospital, Greenbrae, California

Kaiser Permanente South Bay, Harbor City, California

Kaiser Permanente-Irvine, Irvine, California

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

Kaiser Permanente West Los Angeles, Los Angeles, California

Memorial Medical Center, Modesto, California

Kaiser Permanente-Modesto, Modesto, California

Palo Alto Medical Foundation-Camino Division, Mountain View, California

Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California

Sutter Cancer Research Consortium, Novato, California

Kaiser Permanente-Oakland, Oakland, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

Palo Alto Medical Foundation Health Care, Palo Alto, California

Stanford Cancer Institute Palo Alto, Palo Alto, California

Kaiser Permanente - Panorama City, Panorama City, California

Kaiser Permanente-Redwood City, Redwood City, California

Kaiser Permanente-Richmond, Richmond, California

Kaiser Permanente-Riverside, Riverside, California

Kaiser Permanente-Roseville, Roseville, California

Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California

Sutter Roseville Medical Center, Roseville, California

Sutter Medical Center Sacramento, Sacramento, California

Kaiser Permanente-South Sacramento, Sacramento, California

Kaiser Permanente Sacramento Medical Center, Sacramento, California

Kaiser Permanente-San Diego Mission, San Diego, California

Kaiser Permanente-San Diego Zion, San Diego, California

California Pacific Medical Center-Pacific Campus, San Francisco, California

Kaiser Permanente-San Francisco, San Francisco, California

Kaiser Permanente-Santa Teresa-San Jose, San Jose, California

Stanford Cancer Center South Bay, San Jose, California

Kaiser Permanente San Leandro, San Leandro, California

Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California

Kaiser Permanente-San Marcos, San Marcos, California

Kaiser Permanente-San Rafael, San Rafael, California

Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California

Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California

Kaiser Permanente-Santa Rosa, Santa Rosa, California

Sutter Pacific Medical Foundation, Santa Rosa, California

Kaiser Permanente-South San Francisco, South San Francisco, California

Kaiser Permanente-Stockton, Stockton, California

Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California

Kaiser Permanente Medical Center-Vacaville, Vacaville, California

Kaiser Permanente-Vallejo, Vallejo, California

Sutter Solano Medical Center/Cancer Center, Vallejo, California

Kaiser Permanente-Walnut Creek, Walnut Creek, California

John Muir Medical Center-Walnut Creek, Walnut Creek, California

Kaiser Permanente-Woodland Hills, Woodland Hills, California

Conditions: Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Register for Updates

Learn More ›

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

Active Not Recruiting

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

05/08/2025

Locations: Kaiser Permanente-Anaheim, Anaheim, California +94 locations

Kaiser Permanente-Anaheim, Anaheim, California

Kaiser Permanente-Deer Valley Medical Center, Antioch, California

PCR Oncology, Arroyo Grande, California

Sutter Auburn Faith Hospital, Auburn, California

Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California

Kaiser Permanente-Baldwin Park, Baldwin Park, California

Kaiser Permanente-Bellflower, Bellflower, California

Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California

Mills-Peninsula Medical Center, Burlingame, California

Sutter Cancer Centers Radiation Oncology Services-Cameron Park, Cameron Park, California

East Bay Radiation Oncology Center, Castro Valley, California

Valley Medical Oncology Consultants-Castro Valley, Castro Valley, California

John Muir Medical Center-Concord, Concord, California

Sutter Davis Hospital, Davis, California

Epic Care-Dublin, Dublin, California

Bay Area Breast Surgeons Inc, Emeryville, California

Epic Care Partners in Cancer Care, Emeryville, California

Kaiser Permanente-Fontana, Fontana, California

Kaiser Permanente-Fremont, Fremont, California

Valley Medical Oncology Consultants-Fremont, Fremont, California

Kaiser Permanente-Fresno, Fresno, California

Glendale Memorial Hospital and Health Center, Glendale, California

Marin Cancer Care Inc, Greenbrae, California

Marin General Hospital, Greenbrae, California

Kaiser Permanente South Bay, Harbor City, California

Kaiser Permanente-Irvine, Irvine, California

Long Beach Memorial Medical Center-Todd Cancer Institute, Long Beach, California

Kaiser Permanente Los Angeles Medical Center, Los Angeles, California

Kaiser Permanente West Los Angeles, Los Angeles, California

Contra Costa Regional Medical Center, Martinez, California

Memorial Medical Center, Modesto, California

Kaiser Permanente-Modesto, Modesto, California

Community Hospital of Monterey Peninsula, Monterey, California

El Camino Hospital, Mountain View, California

Palo Alto Medical Foundation-Camino Division, Mountain View, California

Palo Alto Medical Foundation-Gynecologic Oncology, Mountain View, California

Sutter Cancer Research Consortium, Novato, California

Highland General Hospital, Oakland, California

Alta Bates Summit Medical Center - Summit Campus, Oakland, California

Bay Area Tumor Institute, Oakland, California

Hematology and Oncology Associates-Oakland, Oakland, California

Tom K Lee Inc, Oakland, California

Kaiser Permanente Oakland-Broadway, Oakland, California

Kaiser Permanente-Oakland, Oakland, California

Saint Joseph Hospital - Orange, Orange, California

Ventura County Hematology Oncology Specialists, Oxnard, California

Desert Regional Medical Center, Palm Springs, California

Palo Alto Medical Foundation Health Care, Palo Alto, California

Stanford Cancer Institute Palo Alto, Palo Alto, California

Kaiser Permanente - Panorama City, Panorama City, California

Valley Medical Oncology Consultants, Pleasanton, California

Pomona Valley Hospital Medical Center, Pomona, California

Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California

Eisenhower Medical Center, Rancho Mirage, California

Kaiser Permanente-Redwood City, Redwood City, California

Kaiser Permanente-Richmond, Richmond, California

Kaiser Permanente-Riverside, Riverside, California

Rohnert Park Cancer Center, Rohnert Park, California

Kaiser Permanente-Roseville, Roseville, California

Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California

Sutter Roseville Medical Center, Roseville, California

The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California

Sutter Medical Center Sacramento, Sacramento, California

Kaiser Permanente-South Sacramento, Sacramento, California

South Sacramento Cancer Center, Sacramento, California

Kaiser Permanente Sacramento Medical Center, Sacramento, California

Saint Helena Hospital, Saint Helena, California

Salinas Valley Memorial, Salinas, California

Kaiser Permanente-San Diego Mission, San Diego, California

Kaiser Permanente-San Diego Zion, San Diego, California

California Pacific Medical Center-Pacific Campus, San Francisco, California

Kaiser Permanente-San Francisco, San Francisco, California

Kaiser Permanente-Santa Teresa-San Jose, San Jose, California

Kaiser Permanente San Leandro, San Leandro, California

Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California

Kaiser Permanente-San Marcos, San Marcos, California

Doctors Medical Center- JC Robinson Regional Cancer Center, San Pablo, California

Kaiser Permanente-San Rafael, San Rafael, California

Breastlink Medical Group Inc, Santa Ana, California

Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California

Palo Alto Medical Foundation-Santa Cruz, Santa Cruz, California

Kaiser Permanente-Santa Rosa, Santa Rosa, California

Sutter Pacific Medical Foundation, Santa Rosa, California

Kaiser Permanente Cancer Treatment Center, South San Francisco, California

Kaiser Permanente-South San Francisco, South San Francisco, California

Kaiser Permanente-Stockton, Stockton, California

Palo Alto Medical Foundation-Sunnyvale, Sunnyvale, California

Northbay Cancer Center, Vacaville, California

Kaiser Permanente Medical Center-Vacaville, Vacaville, California

Kaiser Permanente-Vallejo, Vallejo, California

Sutter Solano Medical Center/Cancer Center, Vallejo, California

Kaiser Permanente-Walnut Creek, Walnut Creek, California

John Muir Medical Center-Walnut Creek, Walnut Creek, California

Kaiser Permanente-Woodland Hills, Woodland Hills, California

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Register for Updates

Learn More ›

Cyclophosphamide Treatment Options in Sacramento, CA

Match to Clinical Trials

Browse Cyclophosphamide Treatment Options in Other California Cities